EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A multi-level characterization of TfR, Mfsd2a and LRP1 in a stem cell derived in vitro model of the blood–brain barrier

Leo König, Marlene Khin, Elena Puris, Sabrina Petralla, Birthe Gericke, Gert Fricker

European Journal of Pharmaceutics and Biopharmaceutics · 2026

DOI: 10.1016/j.ejpb.2026.115111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Leo König und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology and Biopharmacy, Institute for Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg,…. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Low Density Lipoprotein Receptor-Related Protein-1, Receptors, Transferrin, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Federation of Pharmaceutical Industries and Associations, Innovative Medicines Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The blood-brain barrier (BBB) serves as a highly selective interface protecting the central nervous system (CNS) and shielding neural tissue from toxins in the bloodstream, yet its restrictive nature simultaneously poses a significant challenge for therapeutic drug delivery for CNS-related diseases. Consequently, sophisticated in vitro models that accurately mirror the human BBB are essential for evaluating barrier characteristics and drug permeation. Here, we characterize the SBAD0201 hiPSC line differentiated towards a brain microvascular endothelial-like phenotype, that mimics essential characteristics of the human BBB. Our analysis focused on the absolute and relative protein quantification of the transport-relevant targets transferrin receptor (TfR), major facilitator superfamily domain-containing protein 2 transporter (Mfsd2a) and low-density lipoprotein receptor-related protein 1 receptor (LRP1). This study employs a comparative approach with the well-established hCMEC/D3 cell line, a widely used in vitro BBB model. The multi-layered validation, including qRT-PCR, western blot and immunofluorescence, reveals that SBAD0201-derived cells achieve a more mature phenotype. Notably, this model exhibits enhanced barrier integrity and an enriched repertoire of BBB-relevant receptors. These results underline the potential of the SBAD0201 platform as a robust and physiologically relevant tool for CNS research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierLow Density Lipoprotein Receptor-Related Protein-1Receptors, TransferrinInduced Pluripotent Stem CellsHumansCell LineCell DifferentiationEndothelial CellsBiological Transport

Stichwörter der Autor:innen

Blood-brain barrierDrug delivery targetsHuman induced pluripotent stem cellsIn vitro BBB modelMulti-layered characterizationQuantitative targeted absolute proteomicshCMEC/D3

Substanzen

Low Density Lipoprotein Receptor-Related Protein-1Receptors, TransferrinLRP1 protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Technology and Biopharmacy, Institute for Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg, Germany. Electronic address: leo.koenig@uni-heidelberg.de.
  • Department of Pharmaceutical Technology and Biopharmacy, Institute for Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg, Germany. Electronic address: khin@stud.uni-heidelberg.de.
  • A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland. Electronic address: elena.puris@uef.fi.
  • Department of Pharmaceutical Technology and Biopharmacy, Institute for Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg, Germany. Electronic address: sabrina.petralla@uni-heidelberg.de.
  • Department of Pharmaceutical Technology and Biopharmacy, Institute for Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg, Germany. Electronic address: birthe.gericke@uni-heidelberg.de.
  • Department of Pharmaceutical Technology and Biopharmacy, Institute for Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg, Germany. Electronic address: gert.fricker@uni-hd.de.

Förderung

  • European Federation of Pharmaceutical Industries and Associations
  • Innovative Medicines Initiative

Zitieren

APA

König, L., Khin, M., Puris, E., Petralla, S., Gericke, B., & Fricker, G. (2026). A multi-level characterization of TfR, Mfsd2a and LRP1 in a stem cell derived in vitro model of the blood–brain barrier. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115111

Vancouver

König L, Khin M, Puris E, Petralla S, Gericke B, Fricker G. A multi-level characterization of TfR, Mfsd2a and LRP1 in a stem cell derived in vitro model of the blood–brain barrier. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115111

BibTeX
@article{Knig2026,
  author = {König, Leo and Khin, Marlene and Puris, Elena and Petralla, Sabrina and Gericke, Birthe and Fricker, Gert},
  title = {A multi-level characterization of TfR, Mfsd2a and LRP1 in a stem cell derived in vitro model of the blood–brain barrier},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  doi = {10.1016/j.ejpb.2026.115111}
}
Kostenlos starten →